Market Place
Sourcing Support
Enforcement Report - Week of October 9, 2024
09 Oct 2024 //
FDA
Lantheus` Phase 3 Radiotherapy Results Fail To Surpass Pluvicto
16 Sep 2024 //
FIERCE BIOTECH
Novartis gears up for key expansions of 3 cancer drugs
24 Apr 2024 //
FIERCE PHARMA
Novartis plots new Pluvicto filing timeline after waiting for survival results
04 Apr 2024 //
ENDPTS
Novartis` largest Pluvicto plant approved by FDA
06 Jan 2024 //
FIERCE PHARMA
Updated: Novartis `on track` to complete restructuring post Sandoz spin
24 Oct 2023 //
ENDPTS
Novartis Pluvicto® shows benefit in patients with prostate cancer
23 Oct 2023 //
PR NEWSWIRE
Enforcement Report - Week of August 23, 2023
23 Aug 2023 //
FDA
Olaparib Bolsters Lutetium Lu 177 Vipivotide Tetraxetan Activity in mCRPC
11 Jul 2023 //
ONCLIVE
Amid Pluvicto shortage, FDA quickly clears Novartis site
22 Apr 2023 //
FIERCE PHARMA
Novartis halts Pluvicto new patient starts amid supply struggle
28 Feb 2023 //
FIERCE PHARMA
2022 drug approvals: Biopharma delivered 37 new drugs
03 Jan 2023 //
FIERCE PHARMA
Novartis` radioligand therapy Pluvicto wins EU approval for prostate cancer
14 Dec 2022 //
PRESS RELEASE
Novartis receives +ve CHMP opinion for Pluvicto® for patients progressive PSMA
14 Oct 2022 //
GLOBENEWSWIRE
MHRA approves Pluvicto and Locametz for prostate cancer
17 Aug 2022 //
EUROPEANPHARMACEUTICALREVIEW
Novartis’ Pluvicto gets first European approval in GB
11 Aug 2022 //
PHARMAPHORUM
Endocyte & ITM Announce Long-Term Supply Agreement No-Carrier-Added Lutetium-177
09 Jul 2018 //
PRESS RELEASE
Image Following Treatment with 177Lu-PSMA-617 Selected by Nuclear Medicine
26 Jun 2018 //
PRESS RELEASE
Endocyte to Join the Russell 3000® Index
25 Jun 2018 //
PRESS RELEASE
Endocyte Announces Presentations on PSMA-617 at the 2018 Society
22 Jun 2018 //
PRESS RELEASE
Endocyte Announces Enrollment of 1st Patient Ph3 VISION Trial of 177Lu-PSMA-617
05 Jun 2018 //
PRESS RELEASE
Endocyte Announces Presentation of Ph2 Data from Investigator 177Lu-PSMA-617
16 May 2018 //
PRESS RELEASE
Endocyte Announces Pricing of Public Offering of Common Stock
28 Feb 2018 //
PRESS RELEASE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.